MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 04-18-2026
Ultragenyx Pharmaceutical ROE Ratio 2011-2026 | RARE
Annual ROE Ratio Ultragenyx Pharmaceutical
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 718.75 | -222.95 | -220.26 | -200.69 | -49.21 | -16.16 | -61.6 | -32.45 | -78.79 | -51.87 | -27.42 | -32.34 | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 718.75 | -222.95 | -22.92 |
Quarterly ROE Ratio Ultragenyx Pharmaceutical
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -2189.01 | -257.71 | -212.16 | -190.62 | -694.02 | -1158.93 | -1252.36 | -701.64 | -753.92 | -302.8 | -202.26 | -94.73 | -102.55 | -58.09 | -47.36 | -33.32 | -35.4 | -37.92 | -21.68 | -28.31 | -40.58 | -45.79 | -61.52 | -52.89 | -52.97 | -51.77 | -48.33 | -32.45 | -39.34 | -45.67 | -56.02 | -78.79 | -72.52 | -65.55 | -58.55 | -51.87 | -47.23 | -40.93 | -34.52 | -27.42 | -26.07 | -27.25 | -28.99 | -32.34 | -8.16 | 11.67 | 30.5 | 46.87 | 31.75 | 20.48 | 9.0 | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 46.87 | -2189.01 | -183.37 |
ROE Ratio of other stocks in the Biotechnology industry
| Issuer | ROE Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
15.76 | - | 2.43 % | $ 254 M |  Germany |
 |
Aeglea BioTherapeutics
AGLE
|
-21.7 | - | - | $ 1.01 B |  USA |
 |
I-Mab
IMAB
|
-85.31 | - | - | $ 866 M |  China |
 |
Midatech Pharma plc
MTP
|
-330.29 | - | -18.52 % | $ 27.3 M |  Britain |
 |
AIkido Pharma
AIKI
|
-32.34 | - | 1.93 % | $ 17.4 M | USA |
 |
Nymox Pharmaceutical Corporation
NYMX
|
2477.67 | - | -19.68 % | $ 18.4 M |  Canada |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
5.18 | - | - | $ 40.3 B | USA |
 |
Aptorum Group Limited
APM
|
-5.9 | $ 0.9 | -2.33 % | $ 6.62 M | China |
 |
Biophytis SA
BPTS
|
-751.94 | - | -13.47 % | $ 169 M |  France |
 |
Genfit SA
GNFT
|
626.29 | - | 2.54 % | $ 160 B | France |
 |
ACADIA Pharmaceuticals
ACAD
|
30.9 | $ 21.96 | -0.68 % | $ 3.64 B | USA |
 |
RedHill Biopharma Ltd.
RDHL
|
-549.43 | $ 1.02 | -0.49 % | $ 428 M |  Israel |
 |
Allakos
ALLK
|
-110.0 | - | - | $ 28.6 M | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-115.61 | - | -1.52 % | $ 24.7 M | USA |
 |
Advaxis
ADXS
|
196.88 | - | -9.65 % | $ 45.9 M | USA |
 |
AlloVir
ALVR
|
-55.11 | - | 4.14 % | $ 49.1 M | USA |
 |
Ampio Pharmaceuticals
AMPE
|
-256.9 | - | -11.43 % | $ 502 K | USA |
 |
Applied Molecular Transport
AMTI
|
-207.64 | - | - | $ 10.1 M | USA |
 |
Akouos
AKUS
|
-37.09 | - | 0.23 % | $ 488 M | USA |
 |
Aligos Therapeutics
ALGS
|
-45.18 | $ 6.4 | 4.4 % | $ 63.3 M | USA |
 |
Applied Therapeutics
APLT
|
698.49 | - | - | $ 8.42 M | USA |
 |
Aptinyx
APTX
|
-169.38 | - | -39.0 % | $ 4.57 M | USA |
 |
Aridis Pharmaceuticals
ARDS
|
125.33 | - | 17.91 % | $ 11.1 M | USA |
 |
Avenue Therapeutics
ATXI
|
-158.79 | - | -52.27 % | $ 4.45 M | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
12.44 | $ 21.41 | 1.9 % | $ 1 B | USA |
 |
Aravive
ARAV
|
-716.17 | - | -13.39 % | $ 1.45 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
17.55 | - | - | - |  Russia |
 |
AstraZeneca PLC
AZN
|
20.44 | - | - | $ 96.9 B | Britain |
 |
BioDelivery Sciences International
BDSI
|
45.18 | - | -4.8 % | $ 255 M | USA |
 |
Aeterna Zentaris
AEZS
|
-401.79 | - | 5.93 % | $ 314 M | Canada |
 |
Brainstorm Cell Therapeutics
BCLI
|
103.22 | - | -2.5 % | $ 5.88 M | USA |
 |
Kazia Therapeutics Limited
KZIA
|
-132.24 | $ 12.26 | 3.72 % | $ 1.62 B |  Australia |
 |
AgeX Therapeutics
AGE
|
51843.24 | - | -10.17 % | $ 12.2 K | USA |
 |
BioNTech SE
BNTX
|
1.11 | $ 105.46 | -0.09 % | $ 27.2 B | Germany |
 |
BeiGene, Ltd.
BGNE
|
6.58 | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Ayala Pharmaceuticals
AYLA
|
3458.87 | - | - | $ 7.46 M | Israel |
 |
Applied Genetic Technologies Corporation
AGTC
|
-62.37 | - | - | $ 26.5 M | USA |
 |
Aquestive Therapeutics
AQST
|
248.9 | $ 4.08 | 0.25 % | $ 436 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
-8.52 | $ 23.26 | 1.75 % | $ 2.96 B | USA |
 |
Cara Therapeutics
CARA
|
-86.96 | - | -3.03 % | $ 260 M | USA |
 |
Autolus Therapeutics plc
AUTL
|
-161.42 | $ 1.44 | -5.88 % | $ 383 M | Britain |
 |
Aptose Biosciences
APTO
|
93.75 | - | -45.71 % | $ 1.2 M | Canada |
 |
BioXcel Therapeutics
BTAI
|
73.22 | $ 1.06 | -3.64 % | $ 12.9 M | USA |
 |
CASI Pharmaceuticals
CASI
|
-43.38 | - | - | $ 35.4 M | USA |
 |
AVROBIO
AVRO
|
12.83 | - | 1083.1 % | $ 745 M | USA |
 |
Cabaletta Bio
CABA
|
-149.8 | $ 2.95 | -3.28 % | $ 296 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
-175.75 | $ 2.91 | -1.36 % | $ 4.79 M | Israel |
 |
bluebird bio
BLUE
|
-108.93 | - | - | $ 546 M | USA |
 |
CymaBay Therapeutics
CBAY
|
-36.05 | - | - | $ 3.45 B | USA |
 |
Akero Therapeutics
AKRO
|
-33.6 | - | - | $ 3.67 B | USA |